Michael R R Böhm1, Constantin E Uhlig. 1. University Eye Hospital, University Clinics Muenster, Domagkstr. 15, 48129, Muenster, Germany.
Abstract
BACKGROUND: Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome. METHODS: Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30° perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks. RESULTS: Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 μm to 212 μm, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up. CONCLUSIONS: Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.
BACKGROUND: Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome. METHODS: Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30° perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks. RESULTS: Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 μm to 212 μm, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up. CONCLUSIONS: Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.
Authors: Eduardo Cunha de Souza; Evandro Rosa; João Rafael de Oliveira Dias; Fernando Korn Malerbi; Bruno Campelo Leal; Helio Paulo Primiano Junior Journal: Int J Retina Vitreous Date: 2022-06-17